US Human Papilloma Virus/HPV Test and Pap Smear/Test Market (2025-2030)
The US Human Papilloma Virus/HPV Test and Pap Smear/Test Market was valued at $928.4 Million in 2025 and projected to reach to $1436 Million by 2030, representing a compound annual growth rate of 9.1%. The US HPV Test and Pap Smear market is poised for sustained growth through 2030, driven by evolving clinical guidelines that recommend HPV testing as a primary screening method.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Human Papilloma Virus/HPV Test and Pap Smear/Test Market Trends and Insights
- In the US, increasing awareness of cervical cancer prevention and HPV-related diseases is driving demand for both traditional Pap smear tests and advanced HPV testing methodologies.
- The US market benefits from robust healthcare infrastructure, widespread screening programs, and strong reimbursement policies that support routine cervical cancer screening. The US market expansion is fueled by technological advancements in HPV testing, including liquid-based cytology and molecular testing platforms that offer improved accuracy and patient outcomes.
- In the US, the shift toward HPV-primary screening protocols and co-testing strategies reflects evolving clinical guidelines and a commitment to reducing cervical cancer incidence.
- Healthcare providers across the US are increasingly adopting integrated testing solutions that combine HPV detection with cytological assessment, enhancing diagnostic precision and clinical decision-making throughout the forecast period..
Key Market Statistics
- CAGR (2025-2030) 9.1% CAGR
- Market Size, 2025 ~USD 928.4 Million
- Forecast, 2030 ~USD 1436 Million
- Country US
US Human Papilloma Virus/HPV Test and Pap Smear/Test Market Overview
Market Valuation :
The US HPV Test and Pap Smear market is valued at $928.4 million in 2025, with strong growth trajectory driven by preventive healthcare initiatives and insurance coverage expansion across American healthcare systems.
Robust Growth Rate :
The US market is experiencing a 9.1% CAGR through 2030, outpacing many other healthcare segments due to increased cervical cancer screening recommendations and HPV vaccination awareness among US women.
Technological Advancement :
US laboratories are increasingly adopting liquid-based cytology and HPV co-testing methodologies, replacing traditional Pap smears. This shift reflects the American medical community's preference for higher sensitivity and specificity in cervical cancer detection.
Preventive Healthcare Focus :
Rising awareness of HPV-related diseases and cervical cancer prevention in the US is driving demand for routine screening. Updated ASCCP guidelines and increased patient education campaigns are accelerating market adoption across all demographic segments.
US Human Papilloma Virus/HPV Test and Pap Smear/Test Market Dynamics
- Increasing insurance reimbursement rates and expanded access to preventive care services are key growth catalysts.
- The shift from traditional cytology to molecular HPV testing reflects the US healthcare system's commitment to improving cervical cancer detection rates and reducing false negatives. Key market drivers include rising awareness among younger women following HPV vaccination programs, aging populations requiring routine screening, and technological innovations in testing methodologies.
- Healthcare providers across the US are investing in advanced diagnostic infrastructure, while telemedicine platforms are expanding screening accessibility.
- Market consolidation among diagnostic laboratories and increased partnerships between healthcare systems and testing providers will further accelerate growth through 2030..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- The US HPV Test and Pap Smear Market is valued at $928.4 million in 2025 and will reach $1,436.0 million by 2030, growing at a 9.1% CAGR.
- In the US, HPV-primary screening and co-testing strategies are becoming standard clinical practice, driving adoption of advanced molecular testing platforms.
- The US market is supported by strong reimbursement policies, widespread cervical cancer screening programs, and increasing patient awareness of HPV-related health risks.
- Technological innovations in liquid-based cytology and molecular diagnostics are enhancing test accuracy and clinical outcomes across the US healthcare system.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | VAGINAL CANCER SCREENING (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10% from 2025 to 2030 |
| Largest Segment | CERVICAL CANCER SCREENING (Application) |
| Market Size Base Year (Billions) | ~USD 2.45 (2025) |
| Revenue Forecast (Billions) | ~USD 3.94 (2030) |
| Segments Covered | Product & Service, Test Type, Type, Technology, Application, Care Setting |
US Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Hpv Testing
- Pap Tests
By Type
- Co-Testing
- Follow-Up Hpv Testing
- Primary Hpv Testing
By Technology
- Cytology
- Immunodiagnostics
- Molecular Diagnostics
By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
By Care Setting
- Diagnostic Laboratories
- Hospitals
- Physicians’ Offices & Clinics
US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CERVICAL CANCER SCREENING | 852.1 | 891.4 | 939.6 | 999.7 | 1075.5 | 1168 | 1278.6 | 1417 | 8.6 |
| VAGINAL CANCER SCREENING | 66.5 | 70.7 | 75.7 | 81.9 | 89.5 | 98.8 | 109.9 | 123.8 | 10.3 |
| TOTAL | 918.6 | 962.1 | 1015.3 | 1081.6 | 1165 | 1266.9 | 1388.6 | 1540.9 | 8.7 |
Target Audience
- Diagnostic Laboratory Operators : Need market sizing and growth forecasts to justify capital investments in HPV testing infrastructure, staff expansion, and technology upgrades. Require competitive benchmarking data to optimize service offerings and pricing strategies.
- Medical Device & IVD Manufacturers : Require detailed US market analysis to guide product development roadmaps, market entry strategies, and sales forecasting. Critical for understanding adoption rates of new testing methodologies and regulatory pathways specific to American markets.
- Healthcare System Administrators : Need market intelligence to make informed decisions about screening program investments, equipment procurement, and service expansion. Data supports budget justification and strategic planning for cervical cancer prevention initiatives.
- Investment & Private Equity Firms : Require comprehensive market analysis for due diligence on diagnostic testing companies, portfolio optimization, and M&A opportunities. Essential for identifying growth potential and valuation benchmarks in the US healthcare diagnostics sector.
- Healthcare Consultants & Policy Advisors : Need US-specific market data to advise clients on screening program effectiveness, resource allocation, and policy recommendations. Critical for supporting evidence-based decision-making in cervical cancer prevention strategies.
Key Companies in the US Human Papilloma Virus/HPV Test and Pap Smear/Test Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Microbiology & AST (VITEK 2, VITEK MS, VITEK REVEAL, API, ETEST, CHROMID, culture media),Molecular & Syndromic (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, BIOMERIEUX EPISEQ CS),Immunoassay & Sepsis (VIDAS, Hybiome CLIA), |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumer Products,Corporate Assurance,Health and Safety, |
| QUIDEL CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, software),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa, CoolSeal), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and molecular diagnostics assays,PCR and digital PCR solutions, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| ABBOTT | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SEEGENE INC. | South Korea | Public Company | Respiratory infectious disease panels,Sexually transmitted infection and HPV assays,Gastrointestinal and meningitis syndromic panels, |
| SD BIOSENSOR, INC. | South Korea | Public Company | STANDARD Q rapid diagnostics,STANDARD F fluorescence immunodiagnostics,STANDARD E enzyme immunoassay, |
| SANSURE BIOTECH INC. | China | Public Company | Nucleic acid diagnostic reagents (respiratory, HPV, reproductive, blood-borne, GI, others),Rapid antigen tests,Nucleic acid extraction and purification kits, sample reagents, |
| MOLBIO DIAGNOSTICS LIMITED | India | Private Company | Truenat PCR platforms (instruments),Truenat assays and reagents,Disposable POCT devices (dengue, malaria, COVID-19, others), |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.
INTERTEK GROUP PLC
Intertek Group PLC is a British public company established in 1885 with 45,425 employees. The company offers testing, inspection, and certification services across multiple industries.
QUIDEL CORPORATION
Quidel Corporation is a United States public company founded in 1979 with 6,500 employees. The company manufactures rapid diagnostic testing products and molecular assays.
HOLOGIC, INC.
Hologic, Inc. is a private United States company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and medical imaging products.
QIAGEN
QIAGEN is a Dutch public company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and life sciences research tools.
DANAHER CORPORATION
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates across diagnostics, life sciences, and environmental solutions.
ABBOTT
Abbott is a United States public company founded in 1888 with 115,000 employees. The company is a diversified healthcare company providing diagnostics, medical devices, and pharmaceuticals.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees. The company specializes in molecular diagnostic testing and multiplex PCR technology.
SD BIOSENSOR, INC.
SD Biosensor, Inc. is a South Korean public company founded in 1999 with 576 employees. The company develops and manufactures rapid diagnostic test kits and point-of-care devices.
SANSURE BIOTECH INC.
Sansure Biotech Inc. is a Chinese public company founded in 2008 with 2,128 employees. The company develops molecular diagnostic reagents and testing solutions.
MOLBIO DIAGNOSTICS LIMITED
Molbio Diagnostics Limited is a private Indian company founded in 2000. The company develops and manufactures molecular diagnostic devices and testing solutions.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise US market valuation ($928.4M in 2025) and verified 9.1% CAGR projections through 2030. Critical for investment decisions, business planning, and competitive positioning in the American diagnostic testing landscape.
- US-Specific Clinical Insights : Access detailed analysis of American screening guidelines, insurance reimbursement trends, and adoption rates of HPV co-testing versus traditional Pap smears. Essential for understanding US healthcare provider preferences and patient behavior patterns.
- Competitive Landscape Intelligence : Identify leading diagnostic laboratories, testing methodologies gaining traction in US markets, and emerging players disrupting cervical cancer screening. Benchmark your offerings against US market standards and regulatory requirements.
- Strategic Growth Opportunities : Discover high-potential segments within the US market including underserved demographics, telemedicine integration opportunities, and geographic expansion targets. Data-driven insights for market entry and expansion strategies.
- Regulatory & Reimbursement Clarity : Understand US FDA approval pathways, Medicare/Medicaid reimbursement structures, and state-level screening mandates. Critical for product development, pricing strategy, and go-to-market planning in the American healthcare system.
Frequently asked questions
What is the current size of the US HPV Test and Pap Smear Market?
The US HPV Test and Pap Smear Market is valued at $928.4 million in 2025 and is expected to grow to $1,436.0 million by 2030.
What is the projected growth rate for the US market?
The US market is projected to grow at a compound annual growth rate (CAGR) of 9.1% from 2025 to 2030.
What factors are driving growth in the US HPV testing market?
Growth in the US is driven by increased cervical cancer awareness, adoption of HPV-primary screening protocols, technological advancements in molecular testing, and strong reimbursement policies.
How is the US market shifting in testing methodologies?
The US market is transitioning from traditional Pap smear-only approaches to HPV-primary screening and co-testing strategies that combine HPV detection with cytological assessment.
What role does reimbursement play in the US market?
Strong reimbursement policies in the US support routine cervical cancer screening programs and incentivize healthcare providers to adopt advanced HPV testing technologies.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global HPV testing and Pap test market.
Exhaustive secondary research was done to collect information on the HPV testing and Pap test market. The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the HPV testing and Pap test market.
Four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the HPV testing and Pap test market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Human Papillomavirus (HPV) testing identifies the presence of high-risk HPV strains that can lead to cervical cancer and related abnormalities. It is increasingly adopted as a primary screening approach, either independently or alongside Pap testing (co-testing), to assess the risk of cervical disease.
The Papanicolaou (Pap) test is a cytological screening procedure used to detect precancerous and cancerous cells in the cervix, which connects the uterus and vagina. While primarily applied in cervical cancer screening, Pap tests can also detect abnormal or malignant cells in the vaginal canal in some cases.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global HPV testing and Pap test market by product & service, test type, technology, application, care setting, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall HPV testing and Pap test market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the HPV testing and Pap test market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report
Full forecast, segment splits, and company analysis for all Human Papilloma Virus/HPV Test and Pap Smear/Test Market.
- Canada Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Germany Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- France Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Italy Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Spain Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- China Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Japan Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- India Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Brazil Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Mexico Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Saudi Arabia Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UAE Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Asia Pacific Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Latam Human Papilloma Virus/HPV Test and Pap Smear/Test Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
